Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 11/20 | 0.73 |
| ▸ | S1PR4 | O95977 | 8/20 | 0.73 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.73 |
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.73 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.55 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.55 |
| ▸ | GPR183 | P32249 | 1/20 | 0.55 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.55 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.53 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3514080 | 1.00 | S1PR1 (0.73) | S1PR1S1PR4S1PR3S1PR5TNNC1 | |
| SCHEMBL3509655 | 1.00 | S1PR1 (0.73) | S1PR1S1PR4S1PR3S1PR5TNNC1 | |
| SCHEMBL7615633 | 1.00 | S1PR1 (0.73) | S1PR1S1PR4S1PR3S1PR5TNNC1 | |
| SCHEMBL7621645 | 1.00 | S1PR1 (0.73) | S1PR1S1PR4S1PR3S1PR5TNNC1 | |
| SCHEMBL1554624 | 1.00 | S1PR1 (0.73) | S1PR1S1PR4S1PR3S1PR5TNNC1 | |
| SCHEMBL23674394 | 1.00 | S1PR1 (0.73) | S1PR1S1PR4S1PR3S1PR5TNNC1 | |
| SCHEMBL30096682 | 1.00 | S1PR1 (0.73) | S1PR1S1PR4S1PR3S1PR5TNNC1 | |
| Hydrochloric Acid SCHEMBL7614632 | 0.99 | S1PR1 (0.71) | S1PR1S1PR4S1PR3S1PR5TNNC1 | |
| Water SCHEMBL7896708 | 0.99 | S1PR1 (0.71) | S1PR1S1PR4S1PR3S1PR5TNNC1 | |
| SCHEMBL4822056 | 0.99 | S1PR1 (0.70) | S1PR1S1PR4S1PR3S1PR5TNNC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10548858-B2 | Inhibition of sphingosine 1-phosphate receptor for treatment and prevention of lymphedema | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-02-04 | — | — | US | claimed |
| EP-3500308-A1 | INHIBITION OF SPHINGOSINE 1-PHOSPHATE RECEPTOR FOR TREATMENT AND PREVENTION OF LYMPHEDEMA | Memorial Sloan Kettering Cancer Center (US) | 2019-06-26 | — | — | EP | claimed |
| US-20190183818-A1 | Inhibition of Sphingosine 1-Phosphate Receptor for Treatment and Prevention of Lymphedema | MEMORIAL SLOAN KETTERING CANCER CENTER | 2019-06-20 | — | — | US | claimed |
| WO-2018035292-A1 | INHIBITION OF SPHINGOSINE L-PHOSPHATE RECEPTOR FOR TREATMENT AND PREVENTION OF LYMPHEDEMA | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-02-22 | — | — | WO | claimed |
| US-20170020826-A1 | STABILIZATION OF ALCOHOL INTOXICATION-INDUCED CARDIOVASCULAR INSTABILITY | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-01-26 | — | — | US | claimed |
| EP-1915130-B1 | LIQUID FORMULATIONS | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | claimed |
| US-20150283154-A1 | METHODS OF INHIBITING VASCULAR PERMEABILITY AND APOPTOSIS | UNIV CONNECTICUT (US) | 2015-10-08 | — | — | US | claimed |
| US-20150087720-A1 | Dosage Regimen of an S1P Receptor Agonist | NOVARTIS AG (CH) | 2015-03-26 | — | — | US | claimed |
| US-20130065954-A1 | OPHTHALMIC USES OF S1P RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2013-03-14 | — | — | US | claimed |
| EP-2488168-A1 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS | Gemmus Pharma Inc. (US) | 2012-08-22 | — | — | EP | claimed |
| US-20080039530-A1 | Methods of Inhibiting Vascular Permeability and Apoptosis | UNIVERSITY OF CONNECTICUT (US) | 2008-02-14 | — | — | US | claimed |
| WO-2005035003-A9 | COMPOSITIONS AND METHODS FOR INCREASING DRUG EFFICIENCY | DIHEDRON CORP (US) | 2007-08-23 | — | — | WO | claimed |
| US-20070149597-A1 | Medicinal composition as immunosuppressant | SANKYO COMPANY, LIMITED (JP) | 2007-06-28 | — | — | US | claimed |
| EP-1782804-A1 | MEDICINAL COMPOSITION AS IMMUNOSUPPRESSANT | Sankyo Company, Limited (JP) | 2007-05-09 | — | — | EP | claimed |
| WO-2007041368-A2 | DPP IV INHIBITOR FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND GRAFT REJECTION | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | claimed |
| EP-1643983-A2 | METHODS OF INHIBITING VASCULAR PERMEABILITY AND APOPTOSIS | The University of Connecticut (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2005035003-A2 | COMPOSITIONS AND METHODS FOR INCREASING DRUG EFFICIENCY | DIHEDRON CORPORATION (US) | 2005-04-21 | — | — | WO | claimed |
| WO-2005002559-A2 | METHODS OF INHIBITING VASCULAR PERMEABILITY AND APOPTOSIS | UNIVERSITY OF CONNECTICUT (US) | 2005-01-13 | — | — | WO | claimed |
| EP-0778263-B1 | BENZENE COMPOUND AND MEDICINAL USE THEREOF | WELFIDE CORP (JP) | 2002-01-09 | — | — | EP | claimed |
| EP-0778263-A1 | BENZENE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-06-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065954-A1 | OPHTHALMIC USES OF S1P RECEPTOR MODULATORS | S1PR5, S1PR2, S1PR1 | S1PR1 3/4885S1PR4 5/4885S1PR3 4/4885 |
| US-20150283154-A1 | METHODS OF INHIBITING VASCULAR PERMEABILITY AND APOPTOSIS | SPHK1, SPHK2, S1PR2 | S1PR1 4/4885S1PR4 5/4885S1PR3 7/4885 |
| US-20150087720-A1 | Dosage Regimen of an S1P Receptor Agonist | S1PR1, S1PR2, S1PR4 | S1PR1 1/4885S1PR4 3/4885S1PR3 5/4885 |
| US-20070149597-A1 | Medicinal composition as immunosuppressant | HMGCR, SHMT1, CYP11B1 | S1PR1 361/4885S1PR4 1363/4885S1PR3 550/4885 |
| US-20080039530-A1 | Methods of Inhibiting Vascular Permeability and Apoptosis | SPHK2, SPHK1, S1PR2 | S1PR1 4/4885S1PR4 5/4885S1PR3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.